4-1BB chimeric antigen receptors

Area of Science:

• Immunology
• Oncology
• Cell Biology

Background:

• T-cell activation requires both T-cell receptor signals and costimulatory signals for optimal immune responses.
• 4-1BB (CD137, TNFRSF9) is a key costimulatory molecule expressed on activated lymphocytes and other cells, playing a critical role in tumor immunity.

Purpose of the Study:

• To review the properties of 4-1BB and its role in enhancing T-cell function.
• To discuss the design and efficacy of chimeric antigen receptors (CARs) incorporating 4-1BB.
• To explore the therapeutic potential of 4-1BB CARs in cancer treatment.

Main Methods:

• Review of preclinical studies and clinical trial data on 4-1BB CARs.
• Analysis of the signaling pathways induced by 4-1BB ligation.
• Examination of the expression patterns of 4-1BB in immune and non-immune cells.

Main Results:

• 4-1BB ligation triggers cytokine production, antiapoptotic signaling, and augmented immune responses.
• The inclusion of 4-1BB in CARs significantly boosts T-cell expansion and antitumor efficacy.
• Clinical trials indicate promising outcomes for 4-1BB CAR-based therapies.

Conclusions:

• 4-1BB CARs represent a promising strategy for enhancing adoptive T-cell therapy against cancer.
• Further research is needed to fully elucidate the advantages and disadvantages of 4-1BB CARs compared to other costimulatory CAR designs.